Pharma r&d activity surges even without covid-19, says report from the iqvia institute for human data science

Research triangle park, n.c.--(business wire)--despite significant disruption and reprioritization of clinical trial activity during 2020 due to covid-19, r&d activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology, according to a new research report global trends in r&d: overview through 2020 released by the iqvia™ institute for human data science. “the growth in research and development driven by new oncology d
IQV Ratings Summary
IQV Quant Ranking